Fast Market Research

New Market Report: Epilepsy - Pipeline Review, H1 2017

Fast Market Research announces the availability of the new Global Markets Direct report, "Epilepsy - Pipeline Review, H1 2017", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 04/06/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H1 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Get More Details on this Report and a Full Table of Contents at Epilepsy - Pipeline Review, H1 2017

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 15, 17, 2, 71, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).

-The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Companies Mentioned in this Report: Adamas Pharmaceuticals Inc, Advicenne SA, Aeolus Pharmaceuticals Inc, Aequus Pharmaceuticals Inc, Alexza Pharmaceuticals Inc, Anavex Life Sciences Corp, Asklepios BioPharmaceutical Inc, Astellas Pharma Inc, Bial - Portela & Ca SA, BioCrea GmbH, BioHealthonomics Inc, Bionomics Ltd, Biovista Inc, Biscayne Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Cerecor Inc, D-Pharm Ltd, Eisai Co Ltd, Glialogix Inc, Grifols SA, GW Pharmaceuticals Plc, Hyundai Pharmaceutical Co Ltd, INSYS Therapeutics Inc, INVENT Pharmaceuticals Inc, Iproteos SL, Johnson & Johnson, Knopp Biosciences LLC, Lead Discovery Center GmbH, Lipicard Technologies Ltd, Lotus Pharmaceutical Co Ltd, Marathon Pharmaceuticals LLC, Marinus Pharmaceuticals Inc, Medicure Inc, Mitochon Pharmaceuticals Inc, Monosol Rx LLC, Neurelis Inc, Neurocrine Biosciences Inc, NeuroCycle Therapeutics GmbH, Neuron Biopharma SA, Novartis AG, OPKO Health Inc, Ovid Therapeutics Inc, Pfizer Inc, PharmatrophiX Inc, Promius Pharma LLC, Proximagen Ltd, PTC Therapeutics Inc, Retrophin Inc, Sage Therapeutics Inc, Saniona AB, SciFluor Life Sciences LLC, Serina Therapeutics Inc, Shire Plc, SK Biopharmaceuticals Co Ltd, Suda Ltd, Sumitomo Dainippon Pharma Co Ltd, Takeda Pharmaceutical Company Ltd, Trillium Therapeutics Inc, Turing Pharmaceuticals AG, UCB SA, Ultragenyx Pharmaceutical Inc, Upsher-Smith Laboratories Inc, VistaGen Therapeutics Inc, Vitality Biopharma Inc, Xenon Pharmaceuticals Inc, XERIS Pharmaceuticals Inc, Zogenix Inc, Zynerba Pharmaceuticals Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2017
-Atopic Dermatitis - Pipeline Review, H1 2017
-Osteoarthritis - Pipeline Review, H1 2017
-Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017
-Autism - Pipeline Review, H1 2017